USA News
MASON, Ohio --(BUSINESS WIRE)--Aug. 31, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 19 th Annual
MASON, Ohio --(BUSINESS WIRE)--Aug. 4, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2021 financial results. “Our second quarter results were driven by
MASON, Ohio --(BUSINESS WIRE)--Jul. 30, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41 st Annual Growth
MASON, Ohio --(BUSINESS WIRE)--Jul. 7, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release second quarter 2021 financial results on Wednesday, August 4, 2021 .
MASON, Ohio --(BUSINESS WIRE)--Jun. 15, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. Telman and Maggie Yuen have been elected to its Board of Directors. Ms.
FDA approval results in the only label of its kind for more than 3 million patients in the United States , significantly expanding AtriCure’s addressable market Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% difference in effectiveness at 18 months for
FDA approval results in the only label of its kind for more than 3 million patients in the United States , significantly expanding AtriCure’s addressable market Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% difference in effectiveness at 18 months for
MASON, Ohio --(BUSINESS WIRE)--Apr. 27, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2021 financial results. “Our growth in the first quarter is a testament of our
MASON, Ohio --(BUSINESS WIRE)--Apr. 27, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2021 financial results. “Our growth in the first quarter is a testament of our
MASON, Ohio --(BUSINESS WIRE)--Apr. 8, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine (Kris) Johnson has been named Board Chair.
MASON, Ohio --(BUSINESS WIRE)--Apr. 8, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine (Kris) Johnson has been named Board Chair.
MASON, Ohio --(BUSINESS WIRE)--Apr. 6, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2021 financial results on Tuesday, April 27, 2021 .
MASON, Ohio --(BUSINESS WIRE)--Apr. 6, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2021 financial results on Tuesday, April 27, 2021 .
MASON, Ohio --(BUSINESS WIRE)--Mar. 2, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31 st Annual
MASON, Ohio --(BUSINESS WIRE)--Mar. 2, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31 st Annual
© 2021 Atricure, Inc. All Rights Reserved.
